Empagliflozin – 50 mg

Brand:
Cayman
CAS:
864070-44-0
Storage:
-20
UN-No:
Non-Hazardous - /

Inhibiting renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes.{22761,22419} The majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is predominantly expressed in the kidney S1 segment of the proximal tubule. Empagliflozin is a potent SGLT2 inhibitor (IC50 = 3.1 nM) that demonstrates a high degree of selectivity (>2,500-fold) over SGLT1, 4, 5, and 6.{29653} In clinical trials of patients with type 2 diabetes, empagliflozin was shown to lower fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids.{29652}  

 

Available on backorder

SKU: - Category:

Description

A selective SGLT2 inhibitor (IC50 = 3.1 nM) that has been shown in clinical trials of patients with type 2 diabetes to lower fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids


Formal name: (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol

Synonyms:  BI 10773

Molecular weight: 450.9

CAS: 864070-44-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes